| Names | |
|---|---|
| Preferred IUPAC name | (Z)-2-[[2-amino-1,3-thiazol-4-yl]\[[(2-carboxyprop-2-enoyl)oxy]imino]acetyl]amino]-2-methyl-4-oxo-1,2,3-azetidin-1-ium-1-ide-1-carboxylic acid |
| Other names | Azactam Cayston |
| Pronunciation | /æzˈtriː.ə.næm/ |
| Identifiers | |
| CAS Number | 76536-42-8 |
| Beilstein Reference | 71536 |
| ChEBI | CHEBI:2966 |
| ChEMBL | CHEMBL: CHEMBL503 |
| ChemSpider | 2275 |
| DrugBank | DB00355 |
| ECHA InfoCard | 100.060.376 |
| EC Number | 577-85-5 |
| Gmelin Reference | 82242 |
| KEGG | D00223 |
| MeSH | D000071 |
| PubChem CID | 54809 |
| RTECS number | SS7500000 |
| UNII | YKT9TG5EK6 |
| UN number | UN2811 |
| Properties | |
| Chemical formula | C13H17N5O8S2 |
| Molar mass | 435.427 g/mol |
| Appearance | White to yellowish white crystalline powder |
| Odor | Odorless |
| Density | 1.6 g/cm³ |
| Solubility in water | Soluble in water |
| log P | -2.6 |
| Vapor pressure | Vapor pressure: 7.96E-16 mmHg at 25°C |
| Acidity (pKa) | pKa = 2.0 |
| Basicity (pKb) | 6.8 |
| Magnetic susceptibility (χ) | Diamagnetic |
| Refractive index (nD) | 1.64 |
| Viscosity | Viscosity: 1.14 cP |
| Dipole moment | 3.89 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 218.6 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -274.2 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -3930 kJ/mol |
| Pharmacology | |
| ATC code | J01DF01 |
| Hazards | |
| Main hazards | May cause allergy or asthma symptoms or breathing difficulties if inhaled. |
| GHS labelling | GHS labelling of Aztreonam: "Danger; H334: May cause allergy or asthma symptoms or breathing difficulties if inhaled. H317: May cause an allergic skin reaction. P261, P272, P280, P302+P352, P304+P340, P342+P311, P333+P313, P363. |
| Pictograms | 💉🌡️🦠🚫 |
| Signal word | Warning |
| Hazard statements | H317, H334 |
| Precautionary statements | Keep out of reach of children. If medical advice is needed, have product container or label at hand. |
| Flash point | 107.2°C |
| Autoignition temperature | 280°C |
| Lethal dose or concentration | LD50 (mouse, intravenous): 4,300 mg/kg |
| LD50 (median dose) | LD50 (median dose) = 8.392 g/kg (intraperitoneal, mouse) |
| NIOSH | BWN6977800 |
| PEL (Permissible) | PEL (Permissible Exposure Limit) for Aztreonam: Not established |
| REL (Recommended) | 2 g q8h |
| IDLH (Immediate danger) | No IDLH established. |
| Related compounds | |
| Related compounds | Tigemonam Carumonam Cefmetazole Moxalactam |
| Property | Details |
|---|---|
| Product Name | Aztreonam |
| IUPAC Name | (2S,3S)-3-[(2Z)-2-[(Aminothioxomethyl)hydrazinylidene]-2-(2-methyl-4-oxo-1,3-thiazolidin-3-ylidene)acetamido]-2-methyl-4-oxo-1,3-thiazolidine-2-carboxylic acid |
| Chemical Formula | C13H17N5O8S2 |
| Synonyms & Trade Names | Azactam, Lysocin, SQ 26,776, Aztrenonam, Aztreonam for Injection |
| CAS Number | 78110-38-0 |
| HS Code & Customs Classification | 2941.90 (Antibiotics; other)—Classification code depends on local customs requirements and may shift based on formulation and product presentation. |
Aztreonam, structurally classified as a monobactam antibiotic, enters production lines with careful monitoring due to its application in sterile parenteral use. The product’s molecular formula, C13H17N5O8S2, leads to a specific molecular weight which the quality department tracks to verify batch integrity prior to release. Selection of raw materials prioritizes high-purity beta-lactam intermediates to minimize the risk of cross-contamination with other antibiotic classes and to support final product sterility, as required for hospital applications.
Critical checkpoints in manufacturing focus on control of isomeric purity and the presence of beta-lactam ring byproducts. Process engineers select a route that maximizes yield of the (2S,3S) stereochemistry since off-stereoisomers can trigger batch rejection during quality inspection. As the process evolves towards final purification, in-process controls use chromatography to detect hydrazine and thiazolidine-derived impurities, which originate from incomplete reactions or side reactions specific to the selected synthetic route. Variability in impurity profile is minimized with carefully staged purification, validated at each step by both in-house analytic protocols and external pharmacopeia standards where specified for Aztreonam grades intended for regulated markets.
Release criteria never rely on a single analytical value—QC staff review spectral identity, impurity threshold compliance, and parenteral-grade sterility. Some properties, like residual solvent content and water content, are subject to final customer or pharmacopeial requirements. Storage and handling guidance for bulk Aztreonam, as well as formulated forms, incorporates ongoing stability studies conducted per batch and per packaging configuration. For customers seeking powder for solution or direct sterile filling, the production team reviews microbial limits and endotoxin control strategies separately, as these are highly application-sensitive.
HS code classification aligns with “antibiotics; other” unless the finished dose is formulated, which warrants a separate customs tariff. Regulatory classification shifts between territories, so export packaging always reflects the relevant commodity description for that port of entry. Any change in the route, intermediates, or source materials requires a documented revision to batch records and triggers a new round of evaluation for impurity carryover and process robustness. Each department views Aztreonam as an ongoing quality and compliance project, not a static commodity.
Aztreonam is commonly isolated as a white to off-white crystalline powder. The product’s color and form are influenced by the synthesis and purification process. Fine crystalline powders are typical for pharmaceutical APIs, while bulk grades may show slight color variation depending on residual impurities or process deviations. Odor is minimal and not considered a practical identifier in lot release.
Melting point and related thermal properties reflect crystalline purity. API-grade Aztreonam displays discreet melting points, subject to confirmation by differential scanning calorimetry during quality control. Boiling point and flash point data are not typically relevant in standard handling scenarios due to the compound’s solid form and decomposition prior to boiling.
Density is grade-dependent and impacts dosage formulation and packaging. Bulk density may vary, especially between micronized vs. standard monohydrate forms.
Aztreonam remains chemically stable under controlled storage when protected from moisture, heat, and light. The compound’s β-lactam ring is sensitive to strong acids, alkalis, and some nucleophiles, necessitating process discipline to avoid degradation. On exposure to light or elevated temperatures, decomposition products can arise, including inactive or less potent analogs, which QC procedures monitor closely.
Aztreonam’s solubility profile strongly depends on pH. It dissolves well in water or physiological saline but less so in non-polar solvents. Grade, particle size, and residual moisture affect dissolution rate, which must be verified for sterile formulation batches. High-purity grades require aseptic dissolution in WFI (water for injection) under laminar flow for injectable uses. End users should adjust solution pH to optimize solubility and stability as specified by formulation requirements.
Specifications for Aztreonam vary based on intended application: parenteral, oral, or industrial. Key-tested parameters include potency by HPLC, purity by chromatographic methods, water content, endotoxin level, and residual solvents. Acceptance criteria differ between grades and clients, with tighter impurity and pyrogen limits required for injectable use. The final release standard is subject to internal quality control criteria and customer requirements.
The impurity landscape for Aztreonam is shaped by synthesis route and process control. β-lactam analog impurities, residual intermediates, and process-derived by-products are carefully tracked. Specific impurity thresholds comply with pharmacopoeia or client-mandated cutoff levels. Where a new synthetic route is adopted, updated impurity profiling and risk assessment are mandatory prior to batch release.
Our laboratories align with international pharmacopeial procedures—HPLC, IR, UV/VIS, and microbial assays—for product release. Where novel impurities or polymorphs arise, additional method validation supports lot-specific assessment. Detailed test methods and acceptance criteria are defined according to the product’s grade and regulatory status.
Production draws on regionally sourced β-lactam precursors and sulfonic acid intermediates. Choice of supplier hinges on traceable supply, impurity profile, and prior performances in audits. Multi-vendor qualification maintains continuity in the face of supply chain disruptions or regulatory updates. Raw materials undergo identity and purity tests before any process charge.
The main process involves acylation of the β-lactam core followed by sulfonation and diazotization steps in controlled solvent environments. Catalyst use, reaction time, and temperature profiles are refined to limit ring degradation or over-acylation. Route selection evolves according to cost, regulatory guidance, and downstream purification efficiency.
Key control points include real-time pH adjustment, stoichiometric reagent feed rates, and temperature control across all major steps. In-process controls such as TLC and intermediate HPLC scans allow early detection of off-standard conversions. Crystallization and multi-step filtration drive final purification, with activated charcoal or ion-exchange where necessary to remove colored or toxic by-products.
Each batch undergoes a full panel of analytical and microbiological tests before release, including assay, organic impurities, heavy metals, and microbial endotoxins. Only batches passing all specification points proceed to packaging and dispatch. Release standards reflect both internal specification and customer order detail, especially where regulatory filings require batch-certified analytical data.
Aztreonam’s β-lactam moiety provides reactivity under acidic, basic, or nucleophilic conditions. The compound is susceptible to hydrolysis in alkaline medium, which deactivates its antimicrobial properties. Chemical derivatization targets the side chain or sulfonic group for generating analogs with altered spectrum or pharmacokinetics.
Standard modification reactions use aqueous or mixed solvent systems at mild to moderate temperature, typically under nitrogen or argon to prevent oxidative degradation. Temperature and catalyst regimes depend on the desired derivative profile and stability constraints.
Industrial processes can adapt side chain chemistry to develop novel monobactam antibiotics or prodrugs. Each downstream project requires re-validation of impurity pathways and stability testing to meet regulatory and customer expectations.
Long-term storage favors low humidity, and temperature control, with avoidance of direct light. Nitrogen purging or desiccant use is selected for extended shelf life or higher sensitivity grades. Elevated temperatures and humidity risk hydrolysis and off-color development, pushing batches out of specification.
Primary packaging uses high-density polyethylene or glass vials, which prevent moisture ingress and leaching. Product-contact materials are selected for regulatory compliance to minimize interaction and maintain purity.
Shelf life depends on manufacturing route, packaging type, and storage regime. Significant degradation presents as off-color, loss of assay value, or detectable hydrolysis products under HPLC. Routine QC includes periodic stability studies per regulatory requirements.
Aztreonam is classified under the relevant GHS code as a pharmaceutical intermediate. It bears warnings linked to respiratory and dermal sensitization, and laboratory staff require proper barrier precautions during handling.
Personnel should avoid inhalation of powders, skin and eye exposure, and contamination of open wounds. Spill kits and first aid resources are staged throughout production and QC laboratories. Reactive dust clouds require control by local extraction and avoidance of ignition sources.
Acute and sub-chronic toxicity have been characterized in preclinical settings and inform internal exposure guidelines during manufacturing. Airborne weight limits and surface residue thresholds reflect occupational health guidance for antibiotics. Operators in charge of synthesis, granulation, milling, or packaging are fitted with PPE, with work practices monitored and regularly updated to minimize exposure risk.
Current manufacturing output for Aztreonam draws directly from fermentative production and advanced semi-synthetic routes. Process yield increases in recent years have come from multi-stage purification strategies and improved bioconversion efficiency. Available capacity depends on grade: pharmaceutical GMP batches are routinely smaller, matching strict documentation and QC release schedules, while industrial grades support larger-volume output with faster turnover. Production planning hinges on annual raw material contract prices and anticipated shutdowns for line maintenance or regulatory inspections, affecting quarterly availability. Supply peaks align with scheduled hospital formulary cycles and tender launches.
Lead time fluctuates based on grade and upstream API inventory status. For GMP-compliant pharmaceutical batches, typical release lead time ranges from 4 to 8 weeks after order confirmation due to multi-step in-process and final product assay. Non-sterile or technical grades may ship within 10–20 days, subject to order size and replenishment cycles. Minimum order quantities are determined by packaging line configuration and batch scale, often ranging between 1 to 5 kg for GMP pharma grade and upwards of 20 kg for technical bulk.
Packaging adopts moisture- and light-barrier formats with HDPE drums or double PE bags. Final choice depends on customer procurement policies and downstream aseptic compounding requirements. For clinical grades, tamper-evident seals and full traceability from production batch to shipping unit remain standard practice. Industrial grades utilize bulk container options tailored to large-scale manufacturers.
Shipping routes prioritize controlled-temperature freight with established logistics providers familiar with temperature auditing for beta-lactams. Payment terms are typically net 30 to net 60, referencing historical trade risk and destination country. Documentation complies with INCOTERMS 2020 and includes full Certificate of Analysis, batch traceability, and regulatory filing support for international APIs.
Aztreonam’s cost structure links strongly to fermentation input materials, key intermediates such as beta-lactam ring precursors, and downstream purification resins. Price levels react mainly to cyclical changes in fermentation substrate markets (e.g., glucose, corn steep liquor) and the volatility of solvent and reagent markets. Labor and energy costs play a smaller—yet persistent—role for finished API. Seasonal swings in antibiotic feedstock price directly influence batch release costs; price spikes trace back to supply disruptions in core chemical inputs or global logistical slowdowns.
Grade differentiation remains the major driver behind price tiers. Pharmaceutical grades meeting ICH Q7 or cGMP documentation command premiums due to inline QC costs, validated cleaning protocols, and full traceability requirements. Grades intended for industrial or vet applications utilize a less intensive purification regime and a different handling protocol, reflected in price. Customer-specific purity requirements (e.g., not more than certain β-lactam impurity profiles, endotoxin limits) lead to custom quoting. Some end users require additional sterility confirmation or advanced packaging certification (e.g., DMF support, GDP transport audit), creating specific cost uplifts.
Key influences on raw input price include: local availability of fermentation media, fluctuations in crude oil affecting solvent prices, and changes in regulatory environment around hazardous precursor handling. Geopolitical factors—such as anti-dumping duties on Chinese antibiotics or upstream chemical sanctions—can reset cost bases across a production cycle. Plant shutdowns for regulatory rectification or contamination outbreaks in upstream beta-lactam supply chains create ripple effects in both cost and delivery guarantee.
Worldwide, demand for Aztreonam formula fluctuates more in the public sector due to government tendering cycles and antimicrobial stewardship controls. Supply-side consolidation means a majority of industrial volume originates from 5–6 primary producer regions in Asia, with API shipment traced by production lot, regulatory filings, and market release dynamics. European and US importers depend on batch-by-batch regulatory clearance and DMF cross-validation for finished formulation release.
US and EU buyers require multi-year DMF referencing, rigorous batch release testing, and compendial compliance. These add upstream batch hold times and regulatory review costs not seen in industrial or self-dispensing markets. Japanese procurement focuses on trace elemental impurity standards and certified cold chain logistics. Indian manufacturers, leveraging local input cost advantages and extensive fermentation know-how, typically supply for both domestic and re-export consumption. Chinese producers dominate bulk API, facing periodic price competition and regulatory scrutiny around environmental discharge from antibiotic production.
Forward price trends look sensitive to pharma-regulatory stringency, energy price trends, and bioprocess technology adoption rates. Global API costs are projected to tighten mildly due to continued QC upgrades and environmental surcharges in primary producer regions. Increased Western regulatory controls on environmental impact will redirect demand to compliant facilities, pulling up pricing for top-grade API. With the spread of AMR surveillance programs, hospital procurement cycles may see more predictable, slowly rising bulk prices supported by robust QA/QC expectations.
Analysis integrates actual supplier offer data, published contract award results, and input market statistics from regulatory monitoring bodies. Pricing intelligence leverages direct transaction pricing (where available), manufacturing cost modeling, and public sector procurement disclosures. QC verification rates and regulatory update bulletins supplement direct market observation.
Several regions have responded to antimicrobial resistance with public procurement controls and increased post-market API quality inspections. In the last year, shutdowns linked to environmental non-compliance among Asian producers have reshaped export supply lines, redirecting contract volumes. Accreditation programs for sustainable antibiotic API manufacturing have expanded, leading to more traceable procurement cycles.
The regulatory narrative for Aztreonam focuses on enhanced monitoring for mutagenic impurities, especially N-nitrosamine risks. Cross-reference to the latest pharmacopeial monographs and impurity updates remains a gating point for both batch release and market access. European API importers face updated GDP compliance audits and extended documentation for cold chain certification.
Manufacturers respond to regulatory tightening with robust batch segregation strategies, in-process impurity tracking, and upstream supplier auditing. Upgrades to closed-system manufacturing and dedicated containment for beta-lactam lines address cross-contamination risk. Strategic raw material sourcing and dual-plant backup release measures form part of risk mitigation, especially for time-sensitive hospital orders and DMF-backed supply agreements.
Aztreonam occupies a specialized role as a monobactam antibiotic, heavily utilized across pharmaceutical manufacturing. Its main application appears in the formulation of sterile injectable drugs, where purity, sterility, and regulatory compliance take priority every step of the way. In some territories, aztreonam also sees compounding use in hospital pharmacies or direct infusion preparation. Across finished-dosage manufacturers, contract development organizations, and research groups, grade demands shift as requirements grow stricter moving toward end-patient use. On the production floor, injection grade formulations prompt the highest levels of scrutiny, often under GMP or cGMP environments, while non-sterile grades support analytical, research, or process scale-up work.
| Grade | Common Application | Key Application Requirements |
|---|---|---|
| Pharmaceutical Injection Grade | Sterile product manufacturing Clinical and hospital compounding |
Endotoxin control, residual solvent traceability, compliance with pharmacopeial monographs, strict particle spec |
| Pharmaceutical Research Grade | Early R&D Analytical standards Non-sterile development batches |
Primary assay, impurity trend, solubility profile, non-sterility tolerance |
| Custom/Regional Grade | Territory-specific regulatory submission Process adaptation |
Documentation pack, region-driven analytical requirements, batch documentation flexibility |
| Parameter | Grade-Sensitive? | Industrial Impact |
|---|---|---|
| Assay / Purity (%) | Highly sensitive to grade and batch release requirements | Purity fluctuation can impair sterility, injectable product yield, or raise out-of-trend deviations in QA |
| Sterility / Endotoxin | Critical for injection grade; Not considered for research grade |
Uncontrolled endotoxin will fail regulatory release for parenteral products; impacts filtration and filling line |
| Residual Solvents | Grade and region determined | Stringently checked in final API release for injectable grade; certain customers may request expanded panels |
| Heavy Metals | Standardized based on pharmacopoeial monograph, may be custom tightened | Excessive metals drive rejection in regulatory filings and cause downstream contamination in formulation |
| Appearance | Relatively consistent; batch records specify acceptable ranges | Off-color, visible particulate, or non-homogeneous material raises inspection or deviation |
Start with a clear statement of end use. Injectable finished dosage requires full sterility validation from the API batch. Research, R&D, and early-stage companies may operate with research grade, focusing less on sterility and more on primary assay and stability for method development or formulation screening. Any application under regulatory review, such as clinical supply or commercial production, should default to injection or validated regional grade with traceable compliance documentation.
Understand the local regulatory landscape for each batch’s intended destination. GMP or cGMP environments set higher standards for in-process control, impurity profiling, and final release documentation. Regional DMF access might drive a need for bespoke grade release or additional data, such as expanded impurity profile, or alignment with specific pharmacopeial chapters. Early regulatory engagement helps to prevent mismatches between delivered material and submission requirements.
Target purity depends on both the end use and customer process infrastructure. Injectable dosage manufacturers typically demand purity at or above published pharmacopoeial standards along with full impurity trend tracking. Research or analytical development teams may accept wider bands on non-critical impurities if traceability is proven and main peak assurance remains robust. Batch-to-batch reproducibility should be checked especially where process validation links directly to API consistency.
Large-scale manufacturers and CDMOs may require lot reservation, advance capacity booking, and cost predictability for their commercial-scale operations. Small buyers or R&D customers often face batch splitting, lab pack handling, or multi-grade supply needs. Adjust batch sizes and shipment formats with real consumption in mind; communicate volume forecasts early to lock in slot and prevent API shortages, which can interrupt downstream production pipelines.
Before locking in a grade, request a qualification sample and supporting documentation for onsite testing against your internal release criteria. Apply the same analytical methods, dissolution profiles, or process steps as with live manufacturing. Address any observed deviation in assay, purity, or appearance directly with our QC team, allowing for technical justification or tailored solution. Only after sample concordance should the main supply agreement move forward to minimize risk and confirm actual plant compatibility.
Aztreonam production relies on an established quality management system audited by external accredited bodies to ensure consistency with international standards. Audit scope covers documentation, change control, traceability from raw materials through all processing steps, and ongoing supplier risk assessments. Each modification in the process route triggers a documented impact assessment and update of process validation reports. Facility inspections focus on cleaning validation, mixing integrity, and aseptic handling, with cross-contamination prevention integrated into site SOPs. These frameworks shape operator training and batch record review practices.
Certifications at the product level reflect the grade, route, and target application for Aztreonam. Pharmaceutical-grade batches draw on GMP certification with periodic verification of API registration dossiers, while industrial customers may request compliance with additional pharmacopeial monographs or in-house standards. For each lot released, CoAs reference both the latest process validation results and the specific impurity profile expected from the chosen synthetic route. Site-issued statements, such as DMF referencing or CEP listing, depend on customer market requirements and regulatory mandates.
Customers receive full batch documentation, including traceable production logs, impurity trend charts, and analytical results. Document packs are tailored based on order requirements, ranging from simplified QC summaries for technical grades to extended ICH Q7 QP batch release documents for regulated markets. Stability protocols and retention samples can be aligned with contract terms for long-term traceability or dispute resolution. All documentation follows a digital archiving policy audited per the site’s QMS schedule.
Aztreonam batches originate from vertically integrated campaigns with built-in raw material contracts and scheduled line cleaning to avoid carryover. Dedicated production slots are allocated quarterly to maintain responsiveness to demand fluctuations, minimizing cross-industry supply interference. Priority allocation is available for yearly contract holders, with options for phased deliveries or rapid ramp-up in crisis scenarios. Supply risk mitigation draws on dual-source raw material arrangements and monthly inventory reviews to support stable output.
Core API lines run under validated conditions, with real-time monitoring for critical process parameters like temperature profiles, solvent purity, and endpoint confirmation by in-process assay. Line capacity is periodically stress-tested under accelerated order fulfillment programs. Distribution scheduling coordinates directly with downstream sterilization partners if required by the customer’s formulation process. Flex capacity is reserved for emergency backfills or high variability orders in line with quality hold procedures.
Sample requests for Aztreonam processing begin with grade and intended-use disclosure. Production provides a sample drawn from the current validated lot, ensuring traceable origin and matching documentation. Analytical support—ranging from HPLC chromatograms to heavy metal screening—adapts to destination requirements. Application feedback loops include direct technical liaison for process trials, with re-sampling available as formulation or regulatory conditions change. Pre-commercial evaluations can be arranged as part of confidentiality agreements under joint development protocols.
Customers select from schedule-based, call-off, or consignment supply modes depending on downstream process stability and storage capabilities. Pricing structures can mirror batch size or frequency of order, with provisions for surcharge/rebate depending on precursor volatility, freight variables, or regulatory update cycles. Change order procedures support customer-driven adjustments—such as grade swaps or specification tightening—through documented impact analysis and mutual revision of delivery schedules. Cooperation terms allow for joint supply security audits or drop-in process reviews when customer SOPs or regulatory filings evolve.
In the field of aztreonam production, process intensification dominates as a current R&D focus. Advances target step reduction during synthetic routes and streamlining intermediate purification. Researchers at manufacturing sites investigate crystallization improvements to optimize particle size distribution. Specific impurities, such as sulfonate-related side-products, remain under close scrutiny due to regulatory and downstream performance limitations. Quality control teams prioritize analytical method updates, particularly for trace-level detection of related substances, since regional standards may evolve faster than international monographs.
While traditionally centered in injectable formulations for Gram-negative infections, aztreonam discussions increasingly refer to inhalation systems and novel combination therapies targeting resistant strains. Inhalation-grade materials require tighter control of residual solvents and micronization, which compels process engineers to adjust isolation and milling steps. Combination drug platforms often rely on improved solubility and reduced particulates, prompting grade differentiation at the final purification stage.
Manufacturers face recurring technical barriers including removal of isomeric impurities and reduction of process-related residuals derived from sulfonation agents and starting esters. The batch-to-batch control of particle morphology translates into variable flow and compaction during sterile formulation. Targeted efforts with closed-system crystallization and real-time in-process analytics have led to more predictable quality outcomes, though absolute uniformity is grade-dependent and varies with the scale of operation. Continuous review of synthetic chemistry routes responds to global raw material shortages, driving periodic changes in route selection, especially during supply disruptions.
Demand for aztreonam is expected to track global trends in resistant Gram-negative bacterial infections. Shifts in hospital protocols, especially in higher-income regions with robust infection surveillance, sustain baseline market volume. At the same time, emerging market entry is influenced by local regulatory variation, requiring flexible compliance approaches at the manufacturer level. Steady adoption of inhalation and combination formulations is poised to expand application-specific requirements for purity and physical attributes.
Pipeline investments target digital control in batch processing, advanced filtration, and solvent recovery. Adoption of PAT (Process Analytical Technology) improves detection of off-spec batches early in the cycle. Automation of critical steps, such as crystallizer loading and intermediate isolation, supports improved reproducibility in particle size and impurity levels, though these gains reflect capital investments linked to site-specific infrastructure.
Sustainable production attracts focus, especially regarding solvent recycling and minimization of aqueous waste. Projects assessing enzyme-assisted steps examine reductions in process by-products, aiming at both environment and cost benefits. Material sourcing logic increasingly favors feedstocks with known environmental impact profiles, and detailed tracking of supply chain carbon intensity is under implementation, reflecting customer requirements in international markets. Waste treatment integration with local utilities depends on factory location and environmental permitting frameworks.
Technical support staff respond to inquiries covering process adaptation, incompatibility troubleshooting, and material performance under different formulation regimes. For injection-grade and inhalation-grade aztreonam, application-specific guidance on dissolution, filterability, and sterility assurance must account for product grade, end-use, and local pharmacopoeial standards. Customers with advanced delivery projects receive support on risk assessment in scaling up, particularly during technology transfer or regional regulatory filing.
Batch consistency and downstream processability, such as suspension stability or filter clogging, link directly to source material grade and batch attributes. Production teams offer data-driven adjustment recommendations: for example, altering hydration conditions for improved solubility, or advising on micronization protocols for enhanced pulmonary delivery characteristics. All recommendations reflect production history, documented process data, and customer-specific feedback loops rather than theoretical guidance.
Commitments extend to reproducibility investigations, root cause analysis of non-conformities, and structured recall protocols aligned with international regulations. Final release criteria align with internal specifications and documented customer requirements. Any claim triggers an expedited sample re-analysis and, if required, a comprehensive review of batch records, raw material traceability, and deviation logs. Ongoing support includes periodic retraining and process updates to reflect new standards or evolving best practices.
| Key Aspect | Manufacturer’s Technical Focus |
|---|---|
| Raw Material Sourcing | Preference given to traceable sources with demonstrable impurity control and supply stability |
| Process Route Selection | Evaluation shifts based on raw material availability, desired impurity profile, and batch size |
| Impurity Management | Monitored against both internal and external standards; route- and grade-dependent |
| Batch Consistency | Maintained through frequent in-process sampling, advanced analytics, and historical deviation trend reviews |
| Technical Support | Custom guidance based on customer process data and regional regulatory landscapes |
Aztreonam, a monobactam antibiotic, plays a crucial role in the pharmaceutical sector. As a direct manufacturer, our control spans from sourcing raw materials through every stage of synthesis, purification, and quality analysis. Production lines are designed for scale, built to maintain process integrity, and supported by a specialized team with years of industrial plant operation experience. The goal is to supply gram to multi-tonnage quantities for formulation and finished dose manufacturers without shortcuts or reliance on intermediaries.
Aztreonam serves a defined space in the production of sterile antibiotics for gram-negative bacterial infections. Industrial clients rely on consistent batches to supply sterile injectables and complex dosage forms. Beyond pharmaceuticals, research-grade material supports development projects and microbiological reference labs. The material’s role in critical care makes predictable supply and technical transparency essential for B2B buyers in healthcare manufacturing and diagnostics.
Each production batch adheres to stringent analytical controls. In-process monitoring, validated cleaning cycles, and documentation systems are embedded throughout the facility. Finished aztreonam undergoes comprehensive QC checks for identity, assay, purity, and particulate matter. Robust deviation review processes reinforce batch-to-batch continuity. Stability is confirmed with long-term retention samples, ensuring shipment meets both international and specialized customer release criteria, including those for regulated markets.
Packing operations use tested, pharmaceutical-grade containers, including tamper-evident seals and appropriate labeling. For bulk customers, drums and custom sizes are available with batch-specific certificates. Palletization, insulation, and logistics planning protect product integrity through customs and climate variations in transit. Document support for regulated markets accompanies each dispatch. Distribution centers reduce turnaround periods, keeping international and local partners supplied on time.
Technical teams handle detailed requests, from COA comparisons to impurity profiling and method validations. Process chemists coordinate with customer QA for audits and regulatory compliance. Scale-up capabilities meet demand spikes without loss of traceability or control over raw input and solvent grades. Fielding technical queries allows buyers to coordinate project timelines and avoid costly downtime.
Direct access to aztreonam supply supports competitive procurement, secures project timelines, and keeps formulation plans aligned with production window requirements. Planning is more precise as requalification, trial batch, and regulatory submission samples can be scheduled and tracked directly with plant teams. Distributors serving hospitals and clinics value production reliability and packaging compliance, minimizing obstacles in regulatory submissions. Procurement teams gain predictability in budgeting and warehouse management, with scalable volumes for global or domestic markets.
| Focus Area | Manufacturer Capabilities | Value to Buyer |
|---|---|---|
| In-house Production | Full control of raw material inputs, fermentation, and isolation processes | Reliable composition, timely delivery, reduced supplier risk |
| Quality Control | Batch analytics, stability testing, certified procedures | Compliance for regulatory filings, reduced audit burden |
| Packing & Supply | Industrial packing options, batch coding, tailored quantities | Reduced transit issues, flexible inventory integration |
| Technical Support | Ongoing method validation, process transparency, regulatory documentation | Project assurance, faster formulation development |
Our focus remains on stable, compliant supply backed by proven manufacturing capability. Clients in the pharmaceutical industry, research, and healthcare supply chains benefit directly from this approach, without unnecessary complexity or uncertainty.
In more than two decades of manufacturing beta-lactam antibiotics, we have learned careful control at every step is essential. Aztreonam is no exception. Any deviation in its storage conditions during handling or logistics can impact the structure and action of the molecule. That’s not a risk any manufacturer should be willing to take; small changes can prompt degradation and unexpected loss of potency.
We have processed countless batches from synthesis to packaging and tested both the raw sterile API and finished injectable products for shelf life and thermal sensitivity. Aztreonam holds its optimal stability between 2°C and 8°C, which is the standard refrigerated range recognized by regulatory authorities and practiced in our own warehouses and shipping lines. Exposing this antibiotic to higher temperatures, such as those found in unregulated transit or ambient warehousing above 25°C, generates hydrolysis in the beta-lactam ring. This is irreversible and leads to a measurable drop in activity, as our stability data confirm.
Our technical team regularly reviews batch release analytical results and the results are very clear: storage outside the controlled refrigerated zone equals less reliable product at the point of care. Even brief excursions, for instance during loading or customs clearance where refrigeration is lost, cause concern. By contrast, consistent cold storage throughout our logistics chain preserves integrity right up to the vial or sterile pouch. For this reason, our product always ships in insulated containers with calibrated temperature loggers.
We only use packaging validated to maintain the 2°C–8°C requirement from our plant to the customer’s facility. This task extends beyond our own grounds, since product can spend days in transport, at distribution hubs, and in hospital pharmacies before use. There is no margin for error. If vials or sterile powder are exposed to freezing temperatures — below 0°C — we have seen precipitation occur, not to mention risk of glass breakage and moisture uptake once the vial returns to higher temperatures. The raw material’s sensitivity to freeze-thaw cycles guides our storage and handling procedures as well; continuous monitoring is essential.
Within our own operations, environmental chambers constantly log storage temperatures for every batch. Any result outside the set range prompts an immediate investigation. We do not rely on generic warehouse standards or assume cold storage compliance outside our own controls.
Based on our development and commercial experience, we have observed that storing aztreonam at room temperature accelerates degradation, especially if the product remains in these conditions for more than a few weeks. This matches findings from accelerated stability studies and aligns with international guidelines. Our responsibility goes further than just meeting shelf-life requirements — we maintain a strict cold chain so medical staff and patients can trust every vial delivers exactly what our specifications stipulate.
Failing to maintain the recommended temperature erodes the confidence built with healthcare providers and regulatory auditors alike. Temperature abuse leaves chemical markers detectable in routine quality tests, and we include this data in our release documentation for every production lot.
Maintaining that 2°C–8°C environment, from our sterile production line to the destination site, is the front line of quality control for aztreonam. We have equipped our buildings and trucks with automated alerts to ensure product never leaves the validated temperature window. If your facility is part of the supply chain or end-user group, we always encourage storage planning in advance and offer technical support for any specific on-site issues. Keeping aztreonam cold isn’t just regulatory compliance. It’s a matter of protecting the value of every dose produced.
From our vantage point as a direct manufacturer of Aztreonam, clear and transparent procurement requirements support the entire value chain—from formulators to finished dose producers. Bulk orders form the backbone of our manufacturing schedule, prompting us to set parameters on both order volume and delivery expectations that reflect the needs of our large-scale production environment and global batch planning.
Every Aztreonam batch draws on significant resources, precise quality controls, and carefully sequenced production slots. Our minimum order quantity cannot drop below one full drum (typically 25 kg net weight), since partial batches reduce process efficiency and introduce the risk of residual carryover. Each material transfer, blending operation, and lot certification adds fixed overhead that only large lots can absorb effectively. For custom packaging requests or higher purity specifications, minimums may rise if line changeovers or segregated campaigns are required.
We manufacture Aztreonam using multi-step synthesis under strict GMP controls. Every campaign runs on an established timeline: raw materials procurement, staged synthesis and purification, multi-point analytical release, and audit documentation. Most routine lots for established customers ship in six to eight weeks from confirmation of the purchase order, provided our annual allocation planning synchronizes with your volume. Expedited delivery is possible when raw materials and campaign slots remain available, but such acceleration risks disrupting the flow for other long-standing partners. New customers or new regulatory requirements such as additional stability studies can extend timelines. All material undergoes multiple testing cycles for assay, impurities, residual solvents, and bioburden before transfer to our warehouse, never shortcutting protocols for the sake of speed.
Production of sterile APIs like Aztreonam brings unique complexity: sterile filtration, rigorous in-process controls, and validated cleaning runs between each batch. If we fragmented orders into smaller lots or allowed rapid-fire orders outside the production schedule, the whole operation becomes less stable. Fixed minimums let us plan full campaign runs, which yields consistent product quality and market-responsiveness over the course of each year.
From the customer’s perspective, aligning forecasted demand with our batch planning allows us to lock in slots and provision raw materials months ahead. Delays rarely stem from a single bottleneck, but from any disruption along the raw material, synthesis, or packaging cycle—this is why strong forecasts and clear commitments protect market supply. For critical antibiotics like Aztreonam, continuity supports not just business commitments but also public health stakeholders who rely on an uninterrupted supply chain.
We encourage advance engagement on projected requirements to ensure smooth integration into our campaign calendar. Our technical team provides real-time feedback on feasibility for rush or atypical orders and flags any risks needing mitigation. Repeat business, multi-year contracts, and clear planning all support more reliable lead times, while reducing administrative overhead and minimizing costs for everyone involved. For established volume contracts, we hold safety stock in our own warehouse to further hedge against market volatility or emergencies.
To summarize, our bulk procurement process for Aztreonam reflects operational discipline grounded in the realities of large-scale GMP manufacturing. Strong partnerships, open dialogue, and coordinated forecasting remain the most effective ways to secure timely, predictable supply in this highly regulated sector.
Handling the export of Aztreonam—a sterile β-lactam antibiotic produced through rigorous fermentation, purification, and sterile finishing—comes with a set of compliance requirements shaped by the nature of the molecule and its status as a pharmaceutical agent. Several authorities oversee its movement, each with their own rules, and we have seen how important it is to treat each order as an individual project in its own right.
Aztreonam does not simply ship across borders like a commodity chemical. Its classification as an active pharmaceutical ingredient (API) means regulatory agencies such as the US FDA, EMA, NMPA, and others control its import and export at several levels. Our shipment documents include both Certificates of Analysis and Drug Master Files (DMFs) where required, and we retain validated batch records on file for every lot shipped. We engage with regulatory agencies directly, submitting product registrations or specific shipment dossiers in advance, a process which sometimes requires months of lead time depending on the country. Customs clearance alone typically involves controlled substance permits and, in several jurisdictions, pre-clearance inspection or third-party testing at arrival ports.
Our operations staff manages export licenses closely to stay ahead of sudden changes in national regulations. For example, our German and American customers require proof of GMP-compliant production, and our logistics team ensures all supporting documents accompany the consignment, including origin certificates and occasionally reference standards. Each jurisdiction may impose different documentation standards—some want the packing list to match the batch release certificate to the vial, others demand specific storage temperature logs. We use real-time data loggers inside each shipment, not only for our own process validation but to satisfy import inspectors on arrival. No shipment leaves our facility without a full compliance review covering both exporting and importing country requirements.
Even though Aztreonam does not sit on WCO Red List schedules, it can still prompt dual-use or strategic material screens, especially for large commercial consignments. Our compliance desk checks each potential destination not only against pharma lists, but against all controlled goods lists to avoid accidental misclassification. This practice has avoided customs holds and significant demurrage fees. Standard procedure requires us to keep a documented paper trail for each shipment—covering every step from raw material issuance to the delivery of the finished product at the consignee’s address.
Temperature excursions can lead to entire shipments being rejected. Our technical team employs purpose-built cold chain or ambient temperature packaging based on the stability profile registered for that country's pharmacopoeia submission. This means calibrated shippers, validated with our in-house data before use, and insulation rated for multi-day transit periods. Data loggers record interior conditions throughout the journey. Our process includes a pre-shipment hold where quality assurance re-confirms release, so we do not rely on carriers alone for compliance on temperature-sensitive goods.
As the direct manufacturer, we treat compliance as the backbone of international supply, not an afterthought. We monitor evolving global standards, maintain transparent relationships with health authorities, and apply stringent export controls and record-keeping across our entire production and shipping workflow. Aztreonam may be a vital medicine on arrival, but its journey across borders depends on knowledge, experience, and attention to detail from batch release to customs clearance.
For product inquiries, sample requests, quotations or after-sales support, please feel free to contact me directly via sales3@ascent-chem.com, +8615365186327 or WhatsApp: +8615365186327
